Abstract
AbstractExperts claim that some Indian drug manufacturers cut corners and make substandard drugs for markets with nonexistent, underdeveloped, or emerging regulatory oversight, notably Africa. This paper assesses the quality of 1,470 antibiotic and tuberculosis drug samples in solid oral form (tablet or capsule) that claim to be made in India and were sold in Africa, India, and five mid-income non-African countries. We find that 10.9 percent of those products fail a basic assessment of active pharmaceutical ingredients (API), and the majority of the failures are substandard (7 percent) as they contain some correct API but the amount of API is underdosed. The distribution of these substandard products is not random: they are more likely to be found as unregistered products in Africa than in India or non-African countries. Moreover, our finding is robust for manufacturer-drug fixed effects, and is unlikely to be explained by differences in storage conditions as the five Indian cities in our sample are on av...
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
